Addex Therapeutics, a cutting-edge pharmaceutical company specializing in allosteric modulation-based drug discovery and development, has released data showing the promising potential of dipraglurant in treating non-motor symptoms (NMS) experienced by Parkinson’s patients.
Dipraglurant is an mGlu5 NAM that has successfully completed a Phase 2a clinical trial for levodopa induced dyskinesia (PD-LID). These findings demonstrate a great step forward in the mission to help Parkinson’s patients.
The degeneration of the nigro-striatal dopamine pathway has long been known to cause an excessive amount of glutamate activity and contribute to the negative effects of motor symptoms, NMS, and dyskinesias in PD patients.
Recent evidence has shed light on the broad therapeutic potential of mGlu5 inhibitors in treating a range of psychiatric and neurological disorders, making this an exciting development in the field of healthcare. Addex is at the forefront of this research, with its own Head of Translational Science, Dr. Mikhail Kalinichev, leading the charge.
Dipraglurant, an orally administered substance, was recently investigated in a rodent motor symptoms model of Parkinson’s Disease and various neuropsychiatric symptoms such as anxiety, depression and obsessive-compulsive disorder.
Its efficacy was proven by dose-dependent reduction of haloperidol-induced catalepsy, increased punished licks in the Vogel conflict-drinking model, decreased immobility time in the forced swim test and decreased number of buried marbles in the marble-burying test.
Remarkably, dipraglurant was able to cross the blood-brain barrier quickly and had no effect on rotarod performance or locomotor activity. It is an exciting development in the field with its potential to alleviate NMS symptoms.
Addex Therapeutics is thrilled to announce their successful results from the study of dipraglurant, a potential therapy for Parkinson’s disease. According to CEO Tim Dyer, dipraglurant could help reduce the negative symptoms associated with the condition and help improve the quality of life for those who suffer from it.
Moving forward, Addex is exploring the best and most efficient ways to develop dipraglurant for multiple therapeutic applications. With this groundbreaking discovery, Addex is paving the way for a brighter future for those living with Parkinson’s.
About Addex Therapeutics:
Addex Therapeutics is a pioneering clinical-stage pharmaceutical company on a mission to revolutionize the treatment of neurological disorders. Developing an emerging class of novel, orally available small molecule drugs known as allosteric modulators, Addex’s drug discovery platform targets receptors and proteins essential for therapeutic intervention. Their lead drug candidate, ADX71149 (mGlu2 positive allosteric modulator or PAM), is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy.
Additionally, their dipraglurant (mGlu5 negative allosteric modulator or NAM) is being evaluated for future development in a range of indications, and their GABABPAM program has been licensed by Indivior PLC for the development of drug candidates with a focus on substance use disorder.
Addex is also advancing a broad preclinical pipeline for potential treatments for CMT1A, chronic cough, pain, stress related disorders, mild neurocognitive disorders and depression, schizophrenia, and other forms of psychosis. Shares of Addex trade on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol “ADXN”.